Description: BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is based in Melville, New York.
Home Page: www.biorestorative.com
40 Marcus Drive
Melville,
NY
11747
United States
Phone:
631 760 8100
Officers
| Name | Title |
|---|---|
| Mr. Lance Alstodt | Chairman of the Board, President & CEO |
| Mr. Robert Eugene Kristal | Chief Financial Officer |
| Mr. Francisco J. Silva | Chief Scientist, VP of Research & Development, Secretary and Director |
| Stephen Kilmer | Investor Relations Officer |
| Mr. Robert Paccasassi | Vice President of Quality Assurance & Regulatory Compliance |
| Dr. Wayne J. Olan M.D. | Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8663 |
| Price-to-Sales TTM: | 26.0171 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |